Vtv Therapeutics Inc., of High Point, N.C., said it is enrolling the first patients in the company's phase II LOGRA (aLlosteric Oral Glp1 Receptor Agonist) study, a randomized, double-blind, placebo-controlled, parallel group trial of TTP273, an oral, small-molecule GLP-1R agonist.